SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing significant upward momentum as investors react positively to finalized Medicare Advantage rates and a broader push for operational efficiency through AI and cost-cutting measures. The community is actively debating the stock's turnaround potential, with many bulls interpreting the recent price action as a sign of institutional accumulation and a long-term recovery ahead of upcoming earnings.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently gripped by a intense, high-conviction short squeeze, fueled by a significantly constrained float and concentrated ownership by institutional players. The community is actively debating the sustainability of this parabolic move, with many traders warning of extreme volatility and the potential for a swift correction once the market mechanics unwind.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors monitor the company's global expansion into Japan, with sentiment heavily focused on potential international partnerships and a pending U.S. FDA approval for its immunotherapy platform. The community is actively discussing the stock's significant short interest and the hope for upcoming catalysts to drive a breakout in valuation.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors react to a short-seller report that appears to have galvanized the community, leading to heavy buying volume and speculation regarding a potential short squeeze. Discussion is focused on the company's strategic move to redomicile in the U.S., its alignment with major semiconductor players in the AI infrastructure space, and technical momentum suggesting a retest of recent price levels.

Applied Digital Corporation

Applied Digital is trending as investors closely monitor potential hyperscaler lease announcements tied to upcoming financing deadlines and executive compensation filings. The community remains highly focused on cryptic leadership communications and the potential for a major infrastructure partnership, despite broader market volatility and geopolitical concerns weighing on the sector.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospace is trending as investors monitor ongoing supply chain developments and the company's strong industrial backlog, while also navigating recent market-wide volatility during the latest earnings cycle. The community remains focused on the company's long-term growth narrative as a standalone aerospace entity and its role as a key player in global defense and commercial aviation infrastructure.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing a significant surge in investor interest and trading volume, driven by the expansion of its partnership with Nvidia to integrate QNX software into advanced edge AI and robotics platforms. The community is actively discussing the stock's potential for a major revaluation, with many long-term shareholders framing the news as a validation of the company's turnaround and its strategic shift toward becoming a foundational player in physical AI.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following the unexpected announcement that long-time CEO Tim Cook will step down in 2026 to transition into an Executive Chairman role, with current hardware chief John Ternus tapped as his successor. Investors and community members are actively debating the leadership shift, weighing the implications for Apple's future innovation, AI strategy, and the potential for a new era under an engineering-focused CEO.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community debates its long-term potential in AI power infrastructure versus short-term volatility driven by geopolitical tensions and institutional trading. Traders are actively discussing the stock's consolidation patterns and potential for a breakout, while also analyzing its recent board expansion and the company's strategic positioning within high-efficiency power chip markets.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently experiencing heightened investor attention driven by a combination of imminent mission milestones, including two scheduled launches, and strategic expansion through the closure of its Mynaric acquisition. The community is heavily focused on the company's long-term vertical integration, its emerging role in defense-focused hypersonic testing, and its perceived positioning as a primary competitor to larger industry players as demand for space infrastructure accelerates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of...

Robeco Institutional Asset Management B.V. Purchases 151,283 Shares of Alkermes plc $ALKS

Robeco Institutional Asset Management B.V. raised its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 112.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 285,670 shares of the company's stock...

Findings From Long-Term Analysis of the Effects of LYBALVI(olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI (olanzapine and samidorphan) on negative symptoms in adults living with...

Tudor Investment Corp ET AL Takes Position in Alkermes plc $ALKS

Tudor Investment Corp ET AL acquired a new position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange...

Bank of America Forecasts Strong Price Appreciation for Alkermes (NASDAQ:ALKS) Stock

Bank of America boosted their price target on shares of Alkermes from $34.00 to $36.00 and gave the stock a "neutral" rating in a research note on Thursday...

Alkermes (NASDAQ:ALKS) EVP Sells $70,315.38 in Stock

Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP David Joseph Gaffin sold 2,034 shares of the firm's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $34.57...

Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 9,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $35.51, for a total transaction of $319,590.00. Following the transaction, the executive vice president...

Alkermes (NASDAQ:ALKS) Sets New 1-Year High - Still a Buy?

Alkermes (NASDAQ:ALKS) Hits New 1-Year High - Here's What Happened...

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy...

<ul class="summary-bullets"><li>In a mid-stage study, alixorexton demonstrated statistically significant, clinically meaningful and dose-dependent improvements from baseline compared to placebo in wakefulness.</li><li>RBC Capital said the Lilly-Centessa deal highlights large pharma interest in the sleep space and "underscores what could likely be a large indication," which is "favorable" for Alkermes.</li><li>Leerink, who has a ‘Market Perform’ rating on Alkermes shares, opined that the stock could attract interest from large pharma companies seeking a presence in sleep disorders.</li></ul>Shares of Alkermes Plc (ALKS) rallied 15% on Tuesday after pharmaceutical giant Eli Lilly and Company reached an agreement to acquire its peer Centessa for up to $7.8 billion.Centessa is developing a pipeline of orexin receptor 2 (OX2R) agonists to treat excessive daytime sleepiness and disorders of impaired wakefulness. Its lead investigational candidate cleminorexton is under development to treat narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.Alkermes, meanwhile, is also developing an orexin 2 receptor for narcolepsy called alixorexton. In a mid-stage study, alixorexton demonstrated statistically significant, clinically meaningful and dose-dependent improvements from baseline compared to placebo in wakefulness. Alkermes plans to initiate the alixorexton narcolepsy global phase 3 program in early 2026.<h2 class="st-heading-2">Wall Street Weighs In</h2>RBC Capital said the Lilly-Centessa deal highlights large pharma interest in the sleep space and "underscores what could likely be a large indication," which is "favorable" for Alkermes. The firm, which thinks Alkermes' current share price is undervaluing the orexin program alone given comps, notwithstanding the profitable core business, has an ‘Outperform’ rating and $45 price target on the shares.Leerink, who has a ‘Market Perform’ rating on Alkermes shares, opined that the stock could attract interest from large pharma companies seeking a presence in sleep disorders.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ALKS stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/ALKS">ALKS stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-in-anticipation-of-upbeat-q1-delivery-numbers-after-america-expansion-efforts/cZE5cWMRIVp">Nio Stock Rallies In Anticipation Of Upbeat Q1 Delivery Numbers After America Expansion Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alkermes logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes

Shares of Alkermes Plc (ALKS) rallied 15% on Tuesday after pharmaceutical giant Eli Lilly and Company reached an agreement to acquire its peer Centessa for up to $7.8 billion.

Equity

Alkermes, like Centessa, is also developing an orexin 2 receptor for narcolepsy called alixorexton.


Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Current Price	$34.23
Prev Close	$34.53
Open	$34.49
Dividend Yield	0.00%
50-Day Moving Average	$31.41
Beta	0.65
Avg. Volume	2.8M
PE Ratio	23.89

52-Week High	$36.48
52-Week Low	$25.17
Market Capitalization	$5.74B
EPS (Annual)	$1.43
Price to Book	3.12
Revenue Per Employee	$719,950.73

ALKS
Alkermes plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALKS News

ALKSAlkermes plc